Celltrion Extends Remsima SC Indications
Subcutaneous Infliximab Gets Nod Covering IBD And Ankylosing Spondylitis
Celltrion has received a positive opinion from the CHMP for five additional indications for its Remsima SC biosimilar, expanding the scope of the subcutaneous infliximab product that was launched earlier this year.
